NCT03502733 2026-04-13Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaNational Cancer Institute (NCI)Phase 1 Active not recruiting64 enrolled
NCT03586661 2026-03-11Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 1 Active not recruiting31 enrolled